Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo khoa học: " Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer – a phase I study"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: " Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer – a phase I study. | Radiation Oncology BioMed Central Research Open Access Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study U Ganswindt1 W Budach2 V Jendrossek1 G Becker3 M Bamberg1 and C Belka 1 Address 1CCC Tubingen Centre for Genitourinary Oncology Department of Radiation Oncology University of Tubingen Tubingen Germany 2Department of Radiation Oncology University of Dusseldorf Dusseldorf Germany and 3Department of Radiation Oncology Klinik am Eichert Goppingen Germany Email U Ganswindt - ute.ganswindt@med.uni-tuebingen.de W Budach - wilfried.budach@uni-duesseldorf.de V Jendrossek - verena.jendrossek@uni-tuebingen.de G Becker - radioonkologie@KaE.de M Bamberg - michael.bamberg@med.uni-tuebingen.de C Belka - claus.belka@uni-tuebingen.de Corresponding author Published 10 April 2006 Received 25 November 2005 Radiation Oncology2006 1 9 doi 10.1186 1748-717X-1 -9 Accepted 10 April 2006 This article is available from http www.ro-journal.cOm content 1 1 9 2006Ganswindt et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Current approaches for the improvement of bNED for prostate cancer patients treated with radiotherapy mainly focus on dose escalation. However molecularly targeted approaches may also turn out to be of value. In this regard cyclooxygenase COX -2 inhibitors have been shown to exert some anti-tumour activities in human prostate cancer in vivo and in vitro. Although in vitro data indicated that the combination of COX-2 inhibition and radiation was not associated with an increased toxicity we performed a phase I trial using high dose celecoxib together with percutaneous radiation therapy. Methods In order to rule out any increases of more than 20